Core B will provide a variety of IVIHC and TCR reagents, and will perform experiments using these reagents, in support of the research projects. Routine services that will be provided include production of purified recombinant MHC and TCR proteins for tetramer staining and affinity measurements, testing and quality control of tetramer reagents, biophysical measurements of MHC-peptide and MHC-TCR binding affinity and kinetics, and structural characterization of MHC-peptide complexes. This core will also be partly developmental. Developmental services that will be provided include production of MHC heterodimers for characterization of T cell cross reactivity, and creation of improved reagents for analyzing class ll-restricted CD4 T cells based on current understanding of MHC II peptide interactions.
The specific aims of this work are to generate bifunctional MHC dimers to detect cross-reactive T cells, to develop class II MHC tetrarner technology for l-A(b), to measure binding affinity and kinetics for MHC-TCR pairs, and to provide class I MHC tetramer reagents not available from the NIH tetramer facility. Services provided by core B will be used by Project 1 (Swain), Project 2 (Welsh), Project 3 (Tsuda), and Project 4 (Selin), and also by Core C (Huseby),

Public Health Relevance

The MHC and TCR core facility (Core B) will provide centralized protein biochemistry and biophysics services for the research groups studying the immunological aspects of the CD4+ response to viruses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109858-01
Application #
8665108
Study Section
Special Emphasis Panel (ZAI1-ZL-I (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$159,233
Indirect Cost
$63,979
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Urban, Stina L; Berg, Leslie J; Welsh, Raymond M (2016) Type 1 interferon licenses naïve CD8 T cells to mediate anti-viral cytotoxicity. Virology 493:52-9
Bautista, Bianca L; Devarajan, Priyadharshini; McKinstry, K Kai et al. (2016) Short-Lived Antigen Recognition but Not Viral Infection at a Defined Checkpoint Programs Effector CD4 T Cells To Become Protective Memory. J Immunol 197:3936-3949
Stadinski, Brian D; Shekhar, Karthik; Gómez-Touriño, Iria et al. (2016) Hydrophobic CDR3 residues promote the development of self-reactive T cells. Nat Immunol 17:946-55
Zhou, Xin; Hopkins, Jacob W; Wang, Chongkai et al. (2016) IL-2 and IL-6 cooperate to enhance the generation of influenza-specific CD8 T cells responding to live influenza virus in aged mice and humans. Oncotarget 7:39171-39183
Stadinski, Brian D; Obst, Reinhard; Huseby, Eric S (2016) A "hotspot" for autoimmune T cells in type 1 diabetes. J Clin Invest 126:2040-2
Fonseca, Jairo Andres; Cabrera-Mora, Monica; Singh, Balwan et al. (2016) A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP119. Sci Rep 6:34527
Che, Jenny W; Daniels, Keith A; Selin, Liisa K et al. (2016) Heterologous immunity and persistent murine cytomegalovirus infection. J Virol :
Strutt, Tara M; McKinstry, Karl Kai; Kuang, Yi et al. (2016) Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza. J Immunol 197:3260-3270
Wyss, Lena; Stadinski, Brian D; King, Carolyn G et al. (2016) Affinity for self antigen selects Treg cells with distinct functional properties. Nat Immunol 17:1093-101
Devarajan, Priyadharshini; Bautista, Bianca; Vong, Allen M et al. (2016) New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for Influenza. Front Immunol 7:136

Showing the most recent 10 out of 29 publications